MAPK14 and lung cancer: In lung cancer cells, there was no variation (A549) or a slight decrease (H1975, H1650, H1299) of BRCA1 mRNA upon chemotherapy doublet treatment, with no potentiation by the p38 inhibitor (Figure 9).